+1,441.2%
TSLA vs MRNA
+516.4%
+924.8%
-73.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.1% | -3.4% | +3.3% | +0.2% |
| 7D | +3.0% | -10.1% | +13.1% | +4.0% |
| 30D | +11.2% | +126.7% | -115.6% | -4.3% |
| 3M | -7.3% | +184.1% | -191.4% | -23.2% |
| 6M | -7.7% | +143.3% | -151.0% | -22.1% |
| YTD | -18.2% | +359.9% | -378.1% | -37.2% |
| 1Y | +6.0% | +454.2% | -448.2% | -21.5% |
| 3Y | +48.0% | +26.0% | +22.0% | +28.1% |
| 5Y | +46.2% | -70.3% | +116.4% | +37.7% |
| All | +1,441.2% | +516.4% | +924.8% | +1,194.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling